Pacira Pharmaceuticals, Inc. Reports Third Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Wedbush Raises Price Target on Pacira Pharma (PCRX) Following 3Q Beat
October 27, 2015 5:20 PM EDTWedbush reiterated an Outperform rating on Pacira Pharmaceuticals (NASDAQ: PCRX), and raised the price target to $113.00 (from $106.00), following the company's 3Q earnings results. Total revenues of $62.2MM beat consensus of $60.4MM and diluted GAAP EPS of $0.08 also beat consensus of $0.02.
Analyst Liana Moussatos... More
Pacira Pharma (PCRX) Tops Q3 EPS by 20c
October 27, 2015 7:36 AM EDTPacira Pharma (NASDAQ: PCRX) reported Q3 EPS of $0.35, $0.20 better than the analyst estimate of $0.15. Revenue for the quarter came in at $62.2 million versus the consensus estimate of $60.44 million.
Pacira ended the third quarter of 2015 with cash and cash equivalents, short-term investments and long-term investments... More
